iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/23525565
Trial watch: Cardiac glycosides and cancer therapy - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 1;2(2):e23082.
doi: 10.4161/onci.23082.

Trial watch: Cardiac glycosides and cancer therapy

Laurie Menger  1 , Erika Vacchelli, Oliver Kepp, Alexander Eggermont, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Affiliations

Trial watch: Cardiac glycosides and cancer therapy

Laurie Menger et al. Oncoimmunology. .

Abstract

Cardiac glycosides (CGs) are natural compounds sharing the ability to operate as potent inhibitors of the plasma membrane Na+/K+-ATPase, hence promoting-via an indirect mechanism-the intracellular accumulation of Ca2+ ions. In cardiomyocytes, increased intracellular Ca2+ concentrations exert prominent positive inotropic effects, that is, they increase myocardial contractility. Owing to this feature, two CGs, namely digoxin and digitoxin, have extensively been used in the past for the treatment of several cardiac conditions, including distinct types of arrhythmia as well as contractility disorders. Nowadays, digoxin is approved by the FDA and indicated for the treatment of congestive heart failure, atrial fibrillation and atrial flutter with rapid ventricular response, whereas the use of digitoxin has been discontinued in several Western countries. Recently, CGs have been suggested to exert potent antineoplastic effects, notably as they appear to increase the immunogenicity of dying cancer cells. In this Trial Watch, we summarize the mechanisms that underpin the unsuspected anticancer potential of CGs and discuss the progress of clinical studies that have evaluated/are evaluating the safety and efficacy of CGs for oncological indications.

Keywords: Digitalis purpurea; breast carcinoma; estrogen receptor; immunogenic cell death; ouabain; phytoestrogens.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Warren JV. William Withering revisited: 200 years of the foxglove. Am J Cardiol. 1986;58:189–90. doi: 10.1016/0002-9149(86)90276-6. - DOI - PubMed
    1. Gheorghiade M, Adams KF, Jr., Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959–64. doi: 10.1161/01.CIR.0000132482.95686.87. - DOI - PubMed
    1. Runge TM. Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides. Am Heart J. 1977;93:248–55. doi: 10.1016/S0002-8703(77)80319-0. - DOI - PubMed
    1. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer. 2001;1:11. doi: 10.1186/1471-2407-1-11. - DOI - PMC - PubMed
    1. Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, et al. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene. 2012;31:3536–46. doi: 10.1038/onc.2011.521. - DOI - PubMed

LinkOut - more resources